Patents Assigned to EMBER THERAPEUTICS, INC.
  • N-biphenylmethylbenzimidazole modulators of PPARG
    Patent number: 9309227
    Abstract: The invention provides molecular entities that bind with high affinity to PPARG (PPAR?), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: April 12, 2016
    Assignees: The Scripps Research Institute, Ember Therapeutics, Inc.
    Inventors: Theodore Mark Kamenecka, Patrick R. Griffin, Amy S. Ripka, Jeffrey O. Saunders
  • FAT CELLS AND METHODS OF USING THEREOF
    Publication number: 20130195762
    Abstract: Beige cells that contain a reporter gene are disclosed herein. Such cells can be used to identify therapeutic agents for treatment of obesity and its associated disorders, such as diabetes.
    Type: Application
    Filed: January 25, 2013
    Publication date: August 1, 2013
    Applicant: EMBER THERAPEUTICS, INC.
    Inventor: EMBER THERAPEUTICS, INC.